

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

666 Fifth Avenue
New York, New York 10103-3198
FAX: (212) 752-5958

TD

FACSIMILE COVER SHEET

PLEASE TRANSMIT THE FOLLOWING PAGES TO:

NAME: USPTO - NOTICE TO COMPLY OFFICE

COMPANY/FIRM
(LOCATION): USPTO **FAX RECEIVED**

FACSIMILE 703-305-3014 **APR 17 2002**

VOICE PHONE: OFFICE GROUP 1600

From: Norman D. Hanson, Esq. **Phone No.:** 212-318-3091 **Total No. of Pages Sent:**
(Including Cover Sheet) 14

Date: April 17, 2002 **User No.:** 01030 **Flr:** 24 **Matter No.:** 10109097

Return Transmitted Fax To: Laurie Olds

Re:

REMARKS:

If you experience problems with this transmission or have questions, please call 212-318-3250.

CONFIDENTIALITY NOTICE: Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile message is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify the sender by telephone and return the original message to Fulbright & Jaworski L.L.P. at the above address via the U.S. Postal Service at our expense. Thank you.

Houston•Washington, D.C.•Austin•San Antonio•Dallas•London•New York•Los Angeles•Hong Kong

TD

LUD 5752 DIV JEL/NDH (10109097)

VIA FACSIMILE

I hereby certify that this correspondence is being facsimile transmitted to
Commissioner of Patents and Trademarks, Washington, D.C. 20231 on
April 17, 2002.

Fulbright & Jaworski L.L.P.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Jean-Christophe Renauld, et al.
Serial No : 10/026,106
Filed : December 21, 2001
For : ISOLATED CYTOKINE RECEPTOR LICR-2
Art Unit : UNKNOWN
Examiner : UNKNOWN

April 17, 2002

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231


LETTER RESPONSE TO NOTICE TO COMPLY

S I R:

Responsive to the Notice dated April 9, please note that sequences were mailed to the
USPTO on March 28, 2002. Copies of relevant papers are attached.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.


Norman D. Hanson, Esq.
Registration No. 30,946

666 Fifth Avenue
New York, New York 10103-3198
Telephone: 212-318-3168
Telecopier: 212-318-3400

NDH

Case # LUD-5752 DIV Serial No.: 10/026,106
Date Mailed: March 28, 2002 Due Date: 4/13/02

TITLE: ISOLATED CYTOKINE RECEPTOR LICR-2


The following was delivered by First Class Mail to the U.S. Patent and Trademark Office on March 28, 2002.

1. Response to Sequence Letter
2. Paper copy of sequence listing
3. Disk copy of sequence listing

Please charge any additional fees to Deposit Account 50-0624. Please acknowledge receipt of these documents by stamping and returning this postcard.

VIA FIRST CLASS MAIL

I hereby certify that this paper is being facsimile transmitted to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on March 28, 2002.


Laurie Olds

#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Jean-Christophe Renauld, et al.
Serial No. : 10/026,106
Filed : December 21, 2001
For : ISOLATED CYTOKINE RECEPTOR LICR-2
Group Art Unit : UNKNOWN
Examiner : UNKNOWN

March 28, 2002

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

LETTER
NOTICE TO FILE MISSING PARTS

Sir:

Responsive to the Notice dated February 13, 2002, transmitted herewith are paper copy and computer readable forms of sequence information from this application. It is asked that these be made of record herein.

The fee of \$65.00 was paid previously.

The undersigned hereby declares that, to the best of his knowledge, the paper copy and computer readable information are identical to each other and to information set forth in the application as filed. No new matter is believed presented.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By 

Norman D. Hanson
Reg. No. 30,946

666 Fifth Avenue
New York, New York 10103
(212) 318-3000



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/026,106	12/21/2001	Jean-Christophe Renault	LUD-5752 DIV JEL/NDH (101)

CONFIRMATION NO. 7513

FORMALITIES LETTER



OC000000007832803

Fulbright & Jaworski LLP
666 Fifth Avenue
New York, NY 10103

Date Mailed: 04/09/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at
patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*